Patents Assigned to Hadassah Medical Organization
-
Publication number: 20080085866Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.Type: ApplicationFiled: August 13, 2007Publication date: April 10, 2008Applicants: WASHINGTON, UNIVERSITY OF, HADASSAH MEDICAL ORGANIZATION - HADASITInventors: E. Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
-
Patent number: 6348213Abstract: A method of-treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.Type: GrantFiled: May 3, 1994Date of Patent: February 19, 2002Assignees: Yissum Research and Development Co. of The Hebrew University of Jerusalem, Hadassah Medical OrganizationInventors: Yechezkel Barenholz, Elishalom Yechiel
-
Patent number: 5362641Abstract: The present invention relates to a substantially purified heparanase obtained from the human SK-HEP-1 cell line and a method to purify the heparanase from a centrifuged dialyzed homogenate of the SK-HEP-1 cells or a cell culture medium containing the heparanase from the SK-HEP-1 cell line.Type: GrantFiled: January 8, 1992Date of Patent: November 8, 1994Assignee: Hadassah Medical Organization Kiryat HadassahInventors: Zvi Fuks, Israel Vlodavsky
-
Patent number: 5091626Abstract: A method for the ablative reshaping of material surfaces, including the steps of providing a source of an ablative beam having a given average fluence distribution over its cross-sectional extent, determining the ablation curve of the material to be reshaped, selecting, from said ablation curve, an ascending region having an at least approximately constant slope, selecting a beam fluence from among the fluences comprised in said region, irradiating the material surface to be shaped, and controlling the geometry of the material surface thus being reshaped by controlling the total amount of energy per unit area of said surface delivered during said irradiation.Type: GrantFiled: February 2, 1990Date of Patent: February 25, 1992Assignees: Hadassah Medical Organization, Israel Yissum Research Development Company of the Hebrew University of JerusalemInventors: Aaron Lewis, Amihay Fuxbruner, Itzhak Hemo
-
Patent number: 5082851Abstract: The invention provides a composition for protecting the heart from myocardial ischemia and reperfusion injury as well as for reducing post-ischemic damage, improving cardiac function and serving as a hypothermic cardiac preservative solution comprising N,N,N'N'-tetrakis-(2-pyridylmethyl)-ethylenediamine (TPEN) as active ingredient therein.Type: GrantFiled: February 7, 1990Date of Patent: January 21, 1992Assignees: Hadassah Medical Organization, Yissum Research and Development Corporation of the Hebrew University of JerusalemInventors: Jerachmiel Y. Appelbaum, Mordechai Chevion, Gideon Uretzky
-
Patent number: 4898735Abstract: A drug/liposome composition comprising an aqueous suspension of liposomes and, entrapped in the lipid bilayer region of the liposomes, an anthraquinone drug containing quinone and hydroquinone functionalities on adjacent anthracene rings. An iron-specific trihydroxamic chelating agent contained in the bulk aqueous phase of the suspension and a lipophilic free-radical scavenger contained in the bilayer region of the liposome cooperate to reduce chemical modification of both drug and lipid components of the composition. A preferred composition containing doxorubicin and alpha-tocopherol entrapped in the liposomes, and ferrioxamine in the aqueous suspension phase is effective in treating human neoplasms, with significantly reduced side effects over those produced by free-drug administration.Type: GrantFiled: October 12, 1988Date of Patent: February 6, 1990Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Hadassah Medical OrganizationInventors: Yechezkel Barenholz, Alberto Gabizon
-
Patent number: 4812314Abstract: A method of treating a relatively aged animal to reverse age-related changes in the lipid composition of organ and tissue cells, such as heart muscle cells, and the ability of the animal to withstand respiratory stress. A suspension of small unilamellar vesicles composed predominantly of egg phosphatidyl choline is administered parenterally to the animal, preferably over a period of several days and at a dose level of between about 0.1 and 1 grams lipid per kg body weight per day. Changes in the heart muscle cells are reflected in decreased levels of serum creatine phosphokinase. Liposome administration is continued until the serum creatine phosphokinase level drops at least about 50%. Also disclosed are liposome treatment methods for increasing longevity and male fertility.Type: GrantFiled: February 24, 1986Date of Patent: March 14, 1989Assignee: Yissum Research & Dev. Co. of the Hebrew Univ. of Jerusalem and Hadassah Medical OrganizationInventors: Yechezkel Barenholz, Elishalom Yechiel
-
Patent number: 4797285Abstract: A drug/liposome composition comprising an aqueous suspension of liposomes and, entrapped in the lipid bilayer region of the liposomes, an anthraquinone drug containing quinone and hydroquinone functionalities on adjacent anthracene rings. An iron-specific trihydroxamic chelating agent contained in the bulk aqueous phase of the suspension and a lipophilic free-radical scavenger contained in the bilayer region of the liposome cooperate to reduce chemical modification of both drug and lipid components of the composition. A preferred composition containing doxorubicin and alpha-tocopherol entrapped in the liposomes, and ferrioxamine in the aqueous suspension phase is effective in treating human neoplasms, with significantly reduced side effects over those produced by free-drug administration.Type: GrantFiled: December 6, 1985Date of Patent: January 10, 1989Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Hadassah Medical OrganizationInventors: Yechezkel Barenholz, Alberto Gabizon
-
Patent number: 4579730Abstract: The invention provides a pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, the bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, the composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.Type: GrantFiled: May 9, 1984Date of Patent: April 1, 1986Assignee: Hadassah Medical OrganizationInventors: Miriam Kidron, Ehud Ziv, Hanoch Bar-On, Amiram Eldor